Baseline IGF-I Levels Determine Insulin Secretion and Insulin Sensitivity during the First Year on Growth Hormone Therapy in Children Born Small for Gestational Age. Results from a North European Multicentre Study (NESGAS)on behalf of the NESGAS group

Hormone Research in Paediatrics

Volumn 80, Issue 1, 2013, Pages 38-46

  Jensen, Rikke Beck ^a   Thankamony, Ajay ^b   O'Connell, Susan M ^e   Salgin, Burak ^b,f   Kirk, Jeremy ^c   Donaldson, Malcolm ^d   Ivarsson, Sten A ^g   Söder, Olle ^h   Roche, Edna ^e   Hoey, Hilary ^e   Dunger, David B ^b   Juul, Anders ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^d ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^e ADELAIDE AND MEATH HOSPITAL   (Ireland)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^g LUND UNIVERSITY   (Sweden)

^h KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Disposition index; Growth hormone treatment; IGF I resistance; Insulin secretion; Insulin sensitivity; Insulin like growth factor I; Small for gestational age

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; HUMAN GROWTH HORMONE; INSULIN; SOMATOMEDIN C;

ARTICLE; BODY HEIGHT; CHILD; CHILD GROWTH; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SMALL FOR DATE INFANT; TREATMENT DURATION; HORMONAL THERAPY; MULTICENTER STUDY; NORTHERN EUROPEAN; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL;

EID: 84880182576     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000353438     Document Type: Article

References (52)

1. Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM: Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993; 36: 62-67.
2. Sorensen HT, Sabroe S, Rothman KJ, Gillman M, Steffensen FH, Fischer P, Sorensen TI: Birth weight and length as predictors for adult height. Am J Epidemiol 1999; 149: 726-729.
3. Jensen RB, Chellakooty M, Vielwerth S, Vaag A, Larsen T, Greisen G, Skakkebaek NE, Scheike T, Juul A: Intrauterine growth retardation and consequences for endocrine and cardiovascular diseases in adult life: does insulin-like growth factor-I play a role? Horm Res 2003; 60(suppl 3):136-148.
4. Byrne CD: Programming other hormones that affect insulin. Br Med Bull 2001; 60: 153-171.
5. Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, Muinck Keizer-Schrama SM, Drop SL: Children born small for gestational age: do they catch up? Pediatr Res 1995; 38: 267-271.
6. Karlberg J, Albertsson-Wikland K: Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr Res 1995; 38: 733-739.
7. Albertsson-Wikland K, Karlberg J: Natural growth in children born small for gestational age with and without catch-up growth. Acta Paediatr 1994; 399(suppl):64-70.
8. Karlberg J, Luo ZC: Foetal size to final height. Acta Paediatr 2000; 89: 632-636.
9. Dahlgren J, Wikland KA: Final height in short children born small for gestational age treated with growth hormone. Pediatr Res 2005; 57: 216-222.
10. Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A: Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab 2003; 88: 3584-3590.
11. Van Dijk M, Bannink EM, van Pareren YK, Mulder PG, Hokken-Koelega AC: Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (SGA) and untreated short SGA controls. J Clin Endocrinol Metab 2007; 92: 160-165.
12. Carel JC, Chatelain P, Rochiccioli P, Chaussain JL: Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study. J Clin Endocrinol Metab 2003; 88: 1587-1593.
13. Delemarre EM, Rotteveel J, Delemarre-Van De Waal HA: Metabolic implications of GH treatment in small for gestational age. Eur J Endocrinol 2007; 157(suppl 1):S47-S50.
14. De Waal WJ, Hokken-Koelega AC, Stijnen T, Muinck Keizer-Schrama SM, Drop SL: Endogenous and stimulated GH secretion, urinary GH excretion, and plasma IGF-I and IGF-II levels in prepubertal children with short stature after intrauterine growth retardation. The Dutch Working Group on Growth Hormone. Clin Endocrinol (Oxf) 1994; 41: 621-630.
15. Boguszewski M, Rosberg S, Albertsson-Wikland K: Spontaneous 24-hour growth hormone profiles in prepubertal small for gestational age children. J Clin Endocrinol Metab 1995; 80: 2599-2606.
16. De Zegher F, Ong K, van Helvoirt M, Mohn A, Woods K, Dunger D: High-dose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pretreatment GH secretion and associated with a reversible decrease in insulin sensitivity. J Clin Endocrinol Metab 2002; 87: 148-151.
17. Gies I, Thomas M, Tenoutasse S, De Waele K, Lebrethon MC, Beckers D, Francois I, Maes M, Rooman R, de Beaufort C, Massa G, De Schepper J: Insulin sensitivity modulates the growth response during the first year of highdose growth hormone treatment in short prepubertal children born small for gestational age. Horm Res Paediatr 2012; 78: 24-30.
18. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
19. Sorensen K, Aksglaede L, Munch-Andersen T, Aachmann-Andersen NJ, Leffers H, Helge JW, Hilsted L, Juul A: Impact of the growth hormone receptor exon-3 deletion gene polymorphism on glucose metabolism, lipids, and insulin-like growth factor-I levels during puberty. J Clin Endocrinol Metab 2009; 94: 2966-2969.
20. Sorensen K, Aksglaede L, Petersen JH, Andersson AM, Juul A: Serum IGF-1 and insulin levels in girls with normal and precocious puberty. Eur J Endocrinol 2012; 166: 903-910.
21. Niklasson A, Albertsson-Wikland K: Continuous growth reference from 24th week of gestation to 24 months by gender. BMC Pediatr 2008; 8: 8.
22. Nysom K, Molgaard C, Hutchings B, Michaelsen KF: Body mass index of 0 to 45-yearold Danes: reference values and comparison with published European reference values. Int J Obes Relat Metab Disord 2001; 25: 177-184.
23. Wikland KA, Luo ZC, Niklasson A, Karlberg J: Swedish population-based longitudinal reference values from birth to 18 years of age for height, weight and head circumference. Acta Paediatr 2002; 91: 739-754.
24. Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
25. Cobelli C, Toffolo GM, Dalla MC, Campioni M, Denti P, Caumo A, Butler P, Rizza R: Assessment of â-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 2007; 293:E1-E15.
26. Radaelli T, Farrell KA, Huston-Presley L, Amini SB, Kirwan JP, McIntyre HD, Catalano PM: Estimates of insulin sensitivity using glucose and C-peptide from the hyperglycemia and adverse pregnancy outcome glucose tolerance test. Diabetes Care 2010; 33: 490-494.
27. Sas T, de Waal W, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A: Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, doseresponse trial. J Clin Endocrinol Metab 1999; 84: 3064-3070.
28. Phillip M, Lebenthal Y, Lebl J, Zuckerman-Levin N, Korpal-Szczyrska M, Marques JS, Steensberg A, Jons K, Kappelgaard AM, Ibanez L: European multicentre study in children born small for gestational age with persistent short stature: comparison of continuous and discontinuous growth hormone treatment regimens. Horm Res 2009; 71: 52-59.
29. Cutfield WS, Hofman PL, Vickers M, Breier B, Blum WF, Robinson EM: IGFs and binding proteins in short children with intrauterine growth retardation. J Clin Endocrinol Metab 2002; 87: 235-239.
30. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM: Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008; 93: 4210-4217.
31. Lee PA, Kendig JW, Kerrigan JR: Persistent short stature, other potential outcomes, and the effect of growth hormone treatment in children who are born small for gestational age. Pediatrics 2003; 112: 150-162.
32. Ranke MB, Lindberg A, Cowell CT, Wikland KA, Reiter EO, Wilton P, Price DA: Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab 2003; 88: 125-131.
33. Dahlgren J, Kristrom B, Niklasson A, Nierop AF, Rosberg S, Albertsson-Wikland K: Models predicting the growth response to growth hormone treatment in short children independent of GH status, birth size and gestational age. BMC Med Inform Decis Mak 2007; 7: 40.
34. Albertsson-Wikland K, Boguszewski M, Karlberg J: Children born small-for-gestational age: postnatal growth and hormonal status. Horm Res 1998; 49(suppl 2):7-13.
35. Cianfarani S, Geremia C, Scott CD, Germani D: Growth, IGF system, and cortisol in children with intrauterine growth retardation: is catch-up growth affected by reprogramming of the hypothalamic-pituitary-adrenal axis? Pediatr Res 2002; 51: 94-99.
36. Tenhola S, Halonen P, Jaaskelainen J, Voutilainen R: Serum markers of GH and insulin action in 12-year-old children born small for gestational age. Eur J Endocrinol 2005; 152: 335-340.
37. De Zegher F, Du Caju MV, Heinrichs C, Maes M, De Schepper J, Craen M, Vanweser K, Malvaux P, Rosenfeld RG: Early, discontinuous, high-dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years. J Clin Endocrinol Metab 1999; 84: 1558-1561.
38. Boguszewski M, Jansson C, Rosberg S, Bertsson-Wikland K: Changes in serum insulinlike growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age. J Clin Endocrinol Metab 1996; 81: 3902-3908.
39. Hofman PL, Cutfield WS, Robinson EM, Bergman RN, Menon RK, Sperling MA, Gluckman PD: Insulin resistance in short children with intrauterine growth retardation. J Clin Endocrinol Metab 1997; 82: 402-406.
40. Huang Y, Du M, Zhuang S, Shen Z, Li Y: Impaired growth hormone receptor signaling during non-catch-up growth in rats born small for gestational age. Horm Res Paediatr 2010; 74: 106-113.
41. Klammt J, Pfaffle R, Werner H, Kiess W: IGF signaling defects as causes of growth failure and IUGR. Trends Endocrinol Metab 2008; 19: 197-205.
42. Kulkarni RN, Holzenberger M, Shih DQ, Ozcan U, Stoffel M, Magnuson MA, Kahn CR: Beta-cell-specific deletion of the IGF-1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter â-cell mass. Nat Genet 2002; 31: 111-115.
43. LeRoith D, Yakar S: Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007; 3: 302-310.
44. Cutfield WS, Jackson WE, Jefferies C, Robinson EM, Breier BH, Richards GE, Hofman PL: Reduced insulin sensitivity during growth hormone therapy for short children born small for gestational age. J Pediatr 2003; 142: 113-116.
45. Sas T, Mulder P, Aanstoot HJ, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A: Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age. Clin Endocrinol (Oxf) 2001; 54: 243-251.
46. Cutfield WS, Lindberg A, Rapaport R, Wajnrajch MP, Saenger P: Safety of growth hormone treatment in children born small for gestational age: the US trial and KIGS analysis. Horm Res 2006; 65(suppl 3):153-159.
47. De Kort SW, Willemsen RH, van der Kaay DC, Hokken-Koelega AC: The effect of growth hormone treatment on metabolic and cardiovascular risk factors is similar in preterm and term short, small for gestational age children. Clin Endocrinol (Oxf) 2009; 71: 65-73.
48. Willemsen RH, Willemsen SP, Hokken-Koelega AC: Longitudinal changes in insulin sensitivity and body composition of small-forgestational-age adolescents after cessation of growth hormone treatment. J Clin Endocrinol Metab 2008; 93: 3449-3454.
49. Faerch K, Brons C, Alibegovic AC, Vaag A: The disposition index: adjustment for peripheral vs. hepatic insulin sensitivity? J Physiol 2010; 588: 759-764.
50. Moran A, Jacobs DR Jr, Steinberger J, Hong CP, Prineas R, Luepker R, Sinaiko AR: Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes 1999; 48: 2039-2044.
51. Savendahl L, Maes M, Bertsson-Wikland K, Borgstrom B, Carel JC, Henrard S, Speybroeck N, Thomas M, Zandwijken G, Hokken-Koelega A: Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, the Netherlands, and Sweden: preliminary report of three countries participating in the EU SAGhE study. J Clin Endocrinol Metab 2012; 97:E213-E217.
52. Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, Coste J: Longterm mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 2012; 97: 416-425.